It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Active wound dressings are attracting extensive attention in soft tissue repair and regeneration, including bacteria-infected skin wound healing. As the wide use of antibiotics leads to drug resistance we present here a new concept of wound dressings based on the polycaprolactone nanofiber scaffold (NANO) releasing second generation lipophosphonoxin (LPPO) as antibacterial agent. Firstly, we demonstrated in vitro that LPPO released from NANO exerted antibacterial activity while not impairing proliferation/differentiation of fibroblasts and keratinocytes. Secondly, using a mouse model we showed that NANO loaded with LPPO significantly reduced the Staphylococcus aureus counts in infected wounds as evaluated 7 days post-surgery. Furthermore, the rate of degradation and subsequent LPPO release in infected wounds was also facilitated by lytic enzymes secreted by inoculated bacteria. Finally, LPPO displayed negligible to no systemic absorption. In conclusion, the composite antibacterial NANO-LPPO-based dressing reduces the bacterial load and promotes skin repair, with the potential to treat wounds in clinical settings.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry, Prague 6, Czech Republic (GRID:grid.418095.1) (ISNI:0000 0001 1015 3316)
2 Technical University of Liberec, Faculty of Science, Humanities and Education, Liberec 1, Czech Republic (GRID:grid.6912.c) (ISNI:0000000110151740)
3 Pavol Jozef Šafárik University, Laboratory of Cell Interactions, Center of Clinical and Preclinical Research MediPark, Košice, Slovak Republic (GRID:grid.11175.33) (ISNI:0000 0004 0576 0391)
4 University Hospital Královské Vinohrady, Prague Burn Centre, Third Faculty of Medicine, Prague 10, Czech Republic (GRID:grid.412819.7) (ISNI:0000 0004 0611 1895)
5 Pavol Jozef Šafárik University, Laboratory of Cell Interactions, Center of Clinical and Preclinical Research MediPark, Košice, Slovak Republic (GRID:grid.11175.33) (ISNI:0000 0004 0576 0391); East-Slovak Institute of Cardiovascular Diseases, Department of Biomedical Research, Košice, Slovak Republic (GRID:grid.11175.33)
6 The Institute for Nanomaterials, Advanced Technologies and Innovation, Liberec 1, Czech Republic (GRID:grid.6912.c)
7 National Institute of Public Health, Laboratory of Bacterial Genetics, Centre for Epidemiology and Microbiology, Prague 10, Czech Republic (GRID:grid.425485.a) (ISNI:0000 0001 2184 1595)
8 National Institute of Public Health, Unit for Biomedicine and Welfare of Laboratory Animals, Prague 10, Czech Republic (GRID:grid.425485.a) (ISNI:0000 0001 2184 1595)
9 Czech Academy of Sciences V.V.I., Laboratory of Microbial Genetics and Gene Expression, Institute of Microbiology, Prague 4, Czech Republic (GRID:grid.418095.1) (ISNI:0000 0001 1015 3316)
10 National Institute of Public Health, Laboratory of Bacterial Genetics, Centre for Epidemiology and Microbiology, Prague 10, Czech Republic (GRID:grid.425485.a) (ISNI:0000 0001 2184 1595); Charles University, Department of Medical Microbiology, Second Faculty of Medicine, Prague 5, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X)
11 Pavol Jozef Šafárik University, Laboratory of Cell Interactions, Center of Clinical and Preclinical Research MediPark, Košice, Slovak Republic (GRID:grid.11175.33) (ISNI:0000 0004 0576 0391); University Hospital Královské Vinohrady, Prague Burn Centre, Third Faculty of Medicine, Prague 10, Czech Republic (GRID:grid.412819.7) (ISNI:0000 0004 0611 1895); East-Slovak Institute of Cardiovascular Diseases, Department of Biomedical Research, Košice, Slovak Republic (GRID:grid.412819.7)